Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University spinout Mind Foundry is developing software that will help organisations solve problems by unlocking insights hidden deep within their data.

The Oxford team uses advanced machine learning algorithms to solve problems which can only currently be solved by teams of data scientists, or which are currently unsolvable.

Mind Foundry has raised £1.2m in seed funding from private investors and investment company Oxford Sciences Innovation to commercialise the technology.

The company’s technology is based on advanced algorithms and techniques developed by Professors Stephen Roberts and Michael Osborne, who lead Machine Learning research at Oxford’s Department of Engineering Science.

Mind Foundry will build on over 25 years of academic research and applied commercial consulting engagements within the Machine Learning Research Group, a specialist research team within Information Engineering at the University’s Department of Engineering Science.

Stephen Roberts commented: “We live in an era in which the success of organisations and advances in science and technology are increasingly reliant on the fast and accurate analysis of data. But driving these advances is a deluge of data which is outstripping the computational ability to process it, let alone act upon it. We live in an age of big data – but not necessarily big insight. Mind Foundry has the capability to turn this data into actionable insight.” 

Michael Osborne said: “Mind Foundry will enable decision-making from insights generated while the data is being created. This will take organisations beyond business intelligence query tools towards predictive modelling. This is particularly applicable to real-time business recommendations, high-frequency trading, or warning of potential problems or maintenance requirements in industrial systems.”

Mind Foundry’s machine learning techniques have been used by leading firms in the energy, financial services, engineering and manufacturing sectors including BAE Systems, Rolls-Royce and Santos.

The Oxford researchers have won multiple awards including the Rolls-Royce Chairman’s Award for Technical Innovation, the BAE Systems Chairman’s Award and the Google Impact Challenge.

Chief Executive David Pool joins the company from data insight analytics company Ijento and predictive analytics company i4C. “Mind Foundry’s base in Oxford gives us the opportunity to work with some of the finest talent in Machine Learning,” he said.

Isis Innovation managing director Linda Naylor said: “Oxford is recognised as amongst the world’s leading institutions in data analysis. We expect Mind Foundry to be at the forefront of what has been dubbed the ‘algorithm economy’ – the use of algorithms to manage data and guide decision-making.”

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.